Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266088 | 1.00 | RAB9A (0.39) | RAB9ATDP1HRH3NTRK1MEN1 | |
| SCHEMBL3829840 | 1.00 | RAB9A (0.39) | RAB9ATDP1HRH3NTRK1MEN1 | |
| SCHEMBL1267431 | 0.94 | RAB9A (0.37) | RAB9ATDP1HRH3MEN1KMT2A | |
| SCHEMBL1267051 | 0.94 | RAB9A (0.37) | RAB9ATDP1HRH3MEN1KMT2A | |
| SCHEMBL1267214 | 0.93 | RAB9A (0.39) | RAB9ATDP1HRH3MEN1KMT2A | |
| SCHEMBL1266746 | 0.93 | RAB9A (0.39) | RAB9ATDP1HRH3MEN1KMT2A | |
| SCHEMBL1266798 | 0.93 | HRH3 (0.34) | RAB9AHRH3HCRTR1HCRTR2NPSR1 | |
| SCHEMBL1265830 | 0.93 | RAB9A (0.37) | RAB9ATDP1HRH3MEN1KMT2A | |
| SCHEMBL1265851 | 0.91 | MALT1 (0.39) | RAB9AHRH3NTRK1MEN1KMT2A | |
| SCHEMBL1267358 | 0.91 | MALT1 (0.39) | RAB9AHRH3NTRK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521460-B2 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2009-04-21 | — | — | US | claimed |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | CELLTECH R&D LIMITED (GB) | 2007-05-03 | — | — | US | claimed |
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | INTERMUNE, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7521460-B2 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-7482452-B2 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| EP-1638980-B1 | PROCESS FOR PREPARING 3-AMINOTHIENOPYRIDONE DERIVATIVES | UCB PHARMA SA (BE) | 2008-11-05 | — | — | EP | disclosed |
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | CELLTECH R&D LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | MAPK3, MAP3K6, MAP4K1 | RAB9A 1925/4885TDP1 1834/4885HRH3 2718/4885 |
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | MAPKAPK2, MAP3K6, MAP3K2 | RAB9A 2993/4885TDP1 1781/4885HRH3 1577/4885 |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | MAPK1, MAPKAPK2, MAPK6 | RAB9A 891/4885TDP1 193/4885HRH3 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.